Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis